FDA Drug Safety Communication: Liver injury warning to be removed from Letairis (ambrisentan) tablets
The U.S. Food and Drug Administration (FDA) is removing the warning related to liver injury from the boxed warning of the Letairis (ambrisentan) tablet label.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Liver | Urology & Nephrology | Warnings